Tarceva Pancreatic Cancer Survival Benefit Is Small But Clinically Meaningful, Committee Says

Tarceva (erlotinib) survival difference of two weeks to one month, depending on the analysis, is statistically persuasive, FDA’s Oncologic Drugs Advisory Committee says at Sept. 13 meeting.